Corbus Pharmaceuticals Holdings, Inc. (CRBP) AI Stock Analysis

Corbus Pharmaceuticals Holdings, Inc. is a biopharmaceutical firm dedicated to advancing therapies that modulate the immune system, with a focus on immuno-oncology and fibrosis diseases. Its lead compound, lenabasum, is an oral compound designed to selectively activate cannabinoid receptor type 2 and is in Phase II clinical trials for systemic lupus erythematosus. The company is also developing CRB-601 and CRB-602 to target cancer and fibrotic diseases by inhibiting transforming growth factor beta activation. Additionally, Corbus is advancing a cannabinoid receptor type 1 inverse agonist program for metabolic disorders such as obesity, supported by a licensing agreement for the Jenrin library of over 600 compounds.

Corbus Pharmaceuticals experienced significant revenue volatility across past fiscal years, rising from $2.4M in FY2017 to $36.1M in FY2019 before dropping to $3.9M in FY2020 and $881,705 in FY2021. This represented a 5-year revenue CAGR of -14.3% from FY2016 to FY2021. Profitability has remained negative, with net income falling from -$32.4M in FY2017 to -$111.3M in FY2020 and -$45.6M in FY2021, where operating margin reached -6350.1%. For the latest quarter ended June 30, 2026, quarterly revenue growth declined 100.0% year-over-year, leaving trailing twelve months revenue at $0 and diluted EPS at -$6.11.

As of June 30, 2026, Corbus held $117.9M in cash and short-term investments against total debt of $4.3M, resulting in net cash of $113.7M. The company maintains a current ratio of 5.71 and a debt-to-equity ratio of 0.04 across $102.2M in shareholders' equity and $127.0M in total assets. In FY2025, capital expenditures were $7,000. In addition, its 5-year share count change was 364.9%, reflecting past equity dilution.

At a last close of $4.52 on October 16, 2026, Corbus has a market capitalization of $87.4M and an enterprise value of $26.7M. The stock trades at a price-to-sales multiple of 169.9x and a price-to-book ratio of 1.4x, while its EV-to-EBITDA stands at 0.2x. In comparison, the median of its US-listed Healthcare peers trades at a price-to-sales ratio of 4.1x and an EV-to-EBITDA of 12.0x. Over the past year, CRBP fell 76.3%, while the S&P 500 (SPY) gained 16.8%. Over 5 years, the stock returned -85.2% compared to 83.0% for the S&P 500.

Wall Street coverage consists of 9 Strong Buy ratings, 1 Buy rating, and zero Hold, Sell, or Strong Sell ratings. The mean price target is $34.02, representing 652.8% upside compared to the last close of $4.52. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $1.1M and an EPS of -$5.43. For next fiscal year, 9 analysts project revenue of $2.4M and EPS of -$5.51. The company beat EPS estimates in 1 of the last 4 quarters, with the next earnings date set for November 11, 2026.

This page is an AI-written research summary of Corbus Pharmaceuticals Holdings, Inc. (CRBP). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CRBP income statement, CRBP balance sheet, CRBP key metrics, CRBP analyst forecast, CRBP chart. See the CRBP stock overview for the latest quote and news.